DIA Biosimilars 2013

Articles Published in 2008

U.S. Supreme Court Will Not Hear Abigail Alliance v. Eschenbach

Monday, January 14, 2008 05:19 PM

The Abigail Alliance’s petition for a writ of certiorari in The Supreme Court of the United States was denied on January 14. A writ of certiorari is a document which a losing party files with the Supreme Court asking it to review the decision of a lower court.  It includes a list of the parties, a statement of the facts of the case, the legal questions presented for review, and arguments as to why the Court should grant the writ.

More... »

Cenduit: Now with Patient Reminders

Quintiles Expands Central Lab in China; Consolidates Services

Monday, January 14, 2008 07:27 AM

Quintiles has consolidated its China-based Global Central Laboratories and Clinical Development Services (CDS) businesses into a new, 17,000-square-foot facility in Sun Dong Ann Plaza in Beijing. The new site is larger than the CRO’s original laboratory located at the Peking Union Medical College Hospital (PUMCH). The CDS plans to grow to a staff of more than 60 in the next year.

More... »

CRF Health – eCOA Forum

CWWeekly January 7th 2008 Issue

Friday, January 11, 2008 10:28 AM

Top News

More... »

Jobson Medical Information LLC Acquires CenterWatch and New England IRB From Thomson Healthcare

Wednesday, January 9, 2008 07:54 AM

Jobson Medical Information (JMI), a healthcare information and marketing services provider, have acquired the assets of CenterWatch and The New England Institutional Review Board (NEIRB) from Thomson Healthcare, a subsidiary of the Thomson Corporation. Terms of the transaction were not disclosed.

More... »

PPD Completes New Leadership Appointments in Global Move

Monday, January 7, 2008 07:23 AM

Wilmington, N.C.-based contract research organization (CRO) PPD continues revamping its global operations with the appointment of Sebastian Pacios, M.D., hired to lead—as a senior vice president—the CRO’s European, Middle East and Africa operations.

More... »

Gout Drug Shows Promise in Two Pivotal Trials

Friday, January 4, 2008 01:24 PM

Savient Pharmaceuticals reported positive results from two phase III trials, GOUT 1 [Gout Outcomes and Uric acid Treatment] and GOUT 2, of Puricase, a pegylated recombinant urate oxidase for the treatment of gout. The disease is caused by the deposit of urate crystals (via uric acid) in the body's tissues such as joints, tendons and organs. Most traditional treatments have centered on blocking the production of uric acid in the body, whereas Puricase attempts to reduce the levels of uric acid in the blood stream.

More... »

Dissuasion in Recruitment Research

Wednesday, January 2, 2008 11:04 AM

Of all the techniques considered for affecting the behavior of patients and encouraging their clinical trial participation, nary a single researcher has considered the benefits of dissuasion. It is true on its face the concept seems a bit counterintuitive. After all, typical recruitment approaches involve persuasion, enticement, inducement and have, during less proud times, inched closer toward undue influence. What has not yet been explored is the benefit of dissuasion, or discouraging participants from refusing to participate in voluntary clinical research.

More... »

`
CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs